1. Endothelial cannabinoid receptor CB1 deficiency decreases oxLDL uptake and attenuates vascular inflammation in atherosclerosis. (August 2022) Authors: Chen, B.; Prats, R. Guillamat; Li, G.; Jansen, Y.; Prabhu, A.; Remco, M.; Lutz, B.; Hofmann, S.; Herzig, S.; Steffens, S. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study. Issue 3 (4th November 2016) Authors: Kharabian Masouleh, S.; Herzig, S.; Klose, L.; Roggenhofer, E.; Tenckhoff, H.; Kaiser, T.; Thöne‐Otto, A.; Wiese, M.; Berg, T.; Schroeter, M. L.; Margulies, D. S.; Villringer, A. Journal: Journal of viral hepatitis Issue: Volume 24:Issue 3(2017) Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Myeloid cannabinoid receptor CB1 deficiency limits macrophage proliferation and atherosclerosis in a sex-specific manner. (August 2022) Authors: Wang, Y.; Guillamat Prats, R.; Li, G.; Lacy, M.; Jansen, Y.; Lutz, B.; Herzig, S.; Steffens, S. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗